Your shopping cart is currently empty

Thrombin is a "trypsin-like" serine protease that is encoded by the F2 gene in humans. Thrombin is produced by the enzymatic cleavage of two sites on prothrombin by activated Factor X (Xa). Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin. Thrombin is also active in the catalysis of many other coagulation-related reactions.
![coagulation factor II (thrombin) B chain fragment [Homo sapiens]](https://cdn.targetmol.com/group3/M00/02/5B/CgoaEWY7Kv2EXlj9AAAAAAYKAKg911.png)
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $50 | Inquiry | Inquiry | |
| 5 mg | $143 | Inquiry | Inquiry | |
| 10 mg | $235 | Inquiry | Inquiry | |
| 25 mg | $329 | Inquiry | Inquiry |
| Description | Thrombin is a "trypsin-like" serine protease that is encoded by the F2 gene in humans. Thrombin is produced by the enzymatic cleavage of two sites on prothrombin by activated Factor X (Xa). Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin. Thrombin is also active in the catalysis of many other coagulation-related reactions. |
| In vitro | Thrombin is implicated as a major factor in vasospasm following subarachnoid hemorrhage. Blood from a ruptured cerebral aneurysm clot around a cerebral artery, releasing thrombin. This can induce an acute and prolonged narrowing of the blood vessel, potentially resulting in cerebral ischemia and infarction (stroke). Beyond its key role in the dynamic process of thrombus formation, thrombin has a pronounced pro-inflammatory character, which may influence the onset and progression of atherosclerosis [2][3]. |
| Molecular Weight | 1957.26 |
| Formula | C90H137N23O24S |
| Smiles | N[C@@]([H])(CCCCN)C(=O)N1CCC[C@@]1([H])C(=O)N[C@]([H])(C(=O)N[C@](C)([H])C(=O)N[C@]([H])(C/C2=C/C=CC=C2)C(=O)N[C@]([H])(CO)C(=O)N[C@@]([H])(CC(O)=O)C(=O)N[C@]([H])(C/C3=C/C=C(/O)C=C3)C(=O)N[C@@]([H])(C(=O)N[C@]([H])(C/C4=C/N=CN4)C(=O)N5CCC[C@@]5([H])C(=O)N[C@]([H])(C(=O)N[C@]([H])(C[S])C(=O)N[C@@]([H])(CC(C)(C)[H])C(=O)N6CCC[C@]6([H])C(=O)N[C@]([H])(CC(O)=O)C(=O)N[C@]([H])(CCCNC(N)=N)C(=O)O)C(C)(C)[H])[C@@](C)([H])CC)C(C)(C)[H] |
| Relative Density. | no data available |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: ≥195.7 mg/mL, Sonication is recommended. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.